Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

(2013) C. C. Smith et al.   BLOOD

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

(2012) Jorge E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

The clinical development of FLT3 inhibitors in acute myeloid leukemia

(2011) Steven Knapper   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

(2011) J. M. Gozgit et al.   MOLECULAR CANCER THERAPEUTICS

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

(2010) G. Borthakur et al.   HAEMATOLOGICA

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL